NTRK1 and lung adenocarcinoma: However, inconsistent result emerged in a case report, where a patient with advanced lung adenocarcinoma harboring a novel NCOR2-NTRK1 fusion showed disease progression after receiving two cycles of anti-PD-1 inhibitor monotherapy, although the presence of high TMB (58.58 mutations/Mb) and positive PD-L1 expression (20%–30% of the tumor cells) was also observed in this case.